| Course | HS830 Advanced Health Issues and Trends |
|---|---|
| Unit | Unit 4 |
| Paper type | Trend data analysis |
| Length | About 1,240 words, 7 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | Doctor of Health Science (DHSc) |
| Updated | October 2026 |
Free sample paper for HS830 Unit 4
A 1.6-Point Gap and a Popular Explanation: A Unit 4 Trend Data Analysis of Whether Adult Obesity in the United States Has Turned
[Student Name]
Purdue University Global
HS830: Advanced Health Issues and Trends
Unit 4 Trend Data Analysis
[Instructor Name]
[Date]
All series and figures are real and cited to their publishers; the reading of them is the writer's.
The Question
Two claims circulated widely in late 2024. The first is that adult obesity in the United States has stopped rising and may be falling. The second is that GLP-1 receptor agonist drugs, semaglutide and tirzepatide, are the reason. The analysis treats these as separate questions. Whether a trend has turned is a question about data; why it turned is a question about mechanism, and it should only be asked once the first is settled.
Period Before Pattern: The Three Series
National Health and Nutrition Examination Survey (NHANES). NHANES measures height and weight in mobile examination centers on a nationally representative sample, in two-year cycles. Adult obesity prevalence rose from about 30.5 percent in 1999-2000 to 42.4 percent in 2017-2018. The 2019-2020 cycle was halted in March 2020 because of the pandemic, and its partial data were combined with the 2017-2018 cycle to form a prepandemic estimate covering 2017 to March 2020, which put adult obesity at 41.9 percent (Stierman et al., 2021). Fieldwork resumed in August 2021, and the August 2021 to August 2023 cycle put adult obesity at 40.3 percent and severe obesity at 9.4 percent (Emmerich et al., 2024). The denominator is the civilian noninstitutionalized population; the method is measurement, not self-report.
Behavioral Risk Factor Surveillance System (BRFSS). BRFSS is an annual telephone survey run by states with CDC. It asks adults to report their own height and weight. People tend to understate weight and overstate height, so BRFSS prevalence runs several points below NHANES. In 2011 BRFSS added cell phone respondents and changed its weighting method, so estimates before and after 2011 should not be laid on one line. Its strength is state-level detail every year.
Electronic health record analyses. Rader et al. (2024) used records from a large network of health systems covering about 16.7 million adults with measured weights and reported that obesity prevalence, after rising for years, declined slightly in 2023. The denominator is patients who visited a participating health system and were weighed, not the population.
Three series that differ in period, method and denominator cannot be stacked on one axis; each has to be read on its own terms before any of them is compared.
Reading the NHANES Change
The difference between 41.9 and 40.3 percent is 1.6 percentage points. Each estimate carries sampling error; the confidence intervals around estimates of this kind typically span two to three points, and the intervals for these two periods overlap. NCHS did not report the difference as a statistically significant change; it described adult obesity prevalence as essentially unchanged over the past decade while severe obesity continued to rise (Emmerich et al., 2024). There is also a comparability question. The prepandemic estimate blends a full cycle with a partial one, and the 2021-2023 cycle was collected after a disruption that changed who responded to surveys of every kind. Neither problem invalidates the comparison, but both widen the uncertainty around it.
The defensible statement from NHANES is therefore narrow: the long rise in adult obesity appears to have flattened over the last decade, and the newest cycle does not show a statistically significant decline. Severe obesity, the category most associated with costly complications, has not flattened.
Reading the Record-Based Decline
The record-based series has advantages: it is large, recent and measured rather than reported. Its main risk is selection. Patients weighed in a given year are those who came in for care, and people with more chronic conditions visit more often. If the mix of patients seen in 2023 differed from the mix in 2022, for example because people deferred care during the pandemic and returned in later years, prevalence among the weighed could change without any change in the population. Rader et al. (2024) addressed this partly by adjusting for demographics and examining subgroups, and they found the 2023 decline concentrated in the South and among adults aged 56 to 65. A decline in one year of one record network is a signal worth watching, not a trend.
Testing the Drug Explanation for Scale
The drug explanation can be tested before the data settle, by asking whether current use could move national prevalence by the amount claimed. In a May 2024 poll, about 12 percent of adults said they had ever taken a GLP-1 drug and about 6 percent said they were currently taking one, with many using it for diabetes rather than weight loss (Montero et al., 2024). In trials, people with obesity taking semaglutide lost about 15 percent of body weight over 68 weeks (Wilding et al., 2021). But in practice many people stop within a year, often because of cost, side effects or supply, and weight tends to return after stopping.
A rough calculation shows the problem. If 6 percent of adults are taking a drug, and perhaps half of them are using it for weight loss with obesity at baseline, and perhaps a third of those lose enough weight to fall below the obesity threshold, the effect is about one percentage point of national prevalence at most. That is the right order of magnitude to contribute to a small decline, but not to establish one, and it assumes persistence that real-world use has not shown. The analysis therefore frames the answer as not yet: drug use could plausibly contribute to a small change but cannot by itself explain one that the measured series has not confirmed.
Alternative Explanations Worth Holding Open
Two other explanations fit the timing at least as well. The first is mortality: COVID-19 deaths were concentrated among older adults with obesity and related conditions, which would reduce measured prevalence among survivors without any change in weight. The second is measurement itself: survey response fell during and after the pandemic, and if people with obesity were less likely to attend examinations, measured prevalence would fall for that reason alone. NHANES weighting adjusts for some nonresponse, but not for all of it. A credible trend analysis keeps these in view alongside the drug explanation rather than choosing the most newsworthy.
The Next Data That Could Settle the Question
Three releases would change this analysis. The next full NHANES cycle, collected from 2025 onward, would show whether 40.3 percent was the start of a decline or noise around a plateau. Two or three more years of record-based data from the same network, with the same adjustments, would show whether the 2023 dip persisted. And data linking prescriptions to weight in the same patients over two years would show how much of any decline belongs to drug users. Until then, the accurate summary for a health system planning bariatric services or obesity programs is that adult obesity has stopped rising, has not clearly begun to fall, and that drug uptake is not yet large enough to explain a decline even if one is confirmed.
Limits
This analysis relies on published estimates rather than microdata, so the confidence intervals are described rather than recomputed. Poll measures of drug use are self-reported. The scale calculation uses round assumptions and is meant to bound the answer, not to estimate it.
References
Emmerich, S. D., Fryar, C. D., Stierman, B., & Ogden, C. L. (2024). Obesity and severe obesity prevalence in adults: United States, August 2021-August 2023 (NCHS Data Brief No. 508). National Center for Health Statistics. https://doi.org/10.15620/cdc/159281
Montero, A., Sparks, G., Presiado, M., & Hamel, L. (2024). KFF Health Tracking Poll May 2024: The public's use and views of GLP-1 drugs. KFF.
Rader, B., Hazan, R., & Brownstein, J. S. (2024). Changes in adult obesity trends in the US. JAMA Health Forum, 5(12), e243685. https://doi.org/10.1001/jamahealthforum.2024.3685
Stierman, B., Afful, J., Carroll, M. D., Chen, T.-C., Davy, O., Fink, S., Fryar, C. D., Gu, Q., Hales, C. M., Hughes, J. P., Ostchega, Y., Storandt, R. J., & Akinbami, L. J. (2021). National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files: Development of files and prevalence estimates for selected health outcomes (National Health Statistics Reports No. 158). National Center for Health Statistics. https://doi.org/10.15620/cdc:106273
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
The Purdue Global HS830 Unit 4 instructions
The fourth unit generally asks learners to analyze trend data for a health issue, using at least two data sources, and to interpret direction, magnitude and uncertainty. A chart or table is often expected, along with four to six pages of analysis. The usual rule is that each data source must be described before it is interpreted: when it was collected, how, from whom and with what changes in method over time. Many prompts then ask whether a proposed explanation fits the data. Strong papers separate whether a trend has changed from why it changed. Most instructors also expect the paper to name what future data would resolve remaining uncertainty.
Inside the HS830 Unit 4 example
The paper first splits the question into a data question and a mechanism question. Three series are introduced in turn: NHANES with its halted 2019-2020 cycle and combined prepandemic file, BRFSS with its self-report bias and 2011 weighting change, and a health record network covering about 16.7 million adults. The NHANES difference of 1.6 points is then read against overlapping intervals and NCHS's own description of a flat decade. The record-based decline is weighed for selection. A scale test multiplies poll-based uptake by plausible effects and finds about one point at most. Mortality and nonresponse are offered as alternative explanations, and the paper closes by naming three data releases that could settle the question.
HS830 Unit 4 rubric: what earns full points
Trend analysis rubrics typically assign points to data description, accuracy of interpretation, handling of uncertainty, evaluation of explanations and presentation. Data description earns credit when sources are introduced with their methods and limits before results. Interpretation is judged on whether claims match the statistical evidence; calling a nonsignificant change a decline is a frequent deduction. Uncertainty points reward discussion of confidence intervals, revisions and comparability problems. Evaluating explanations carries weight because the course expects learners to test causes against scale and timing. Clear figures, labeled periods and consistent units affect presentation marks. Instructors also look for an ending that tells a health leader what the data can and cannot support today.
HS830 Unit 4 help from the desk
Analyses often start with the most recent number and work backward, which invites overreading a single point. Another mistake is mixing self-reported and measured series on one line without adjustment. Some learners accept a popular explanation because it is plausible, without checking whether it is large enough. Others ignore that data collection changed during the pandemic. Leaving out confidence intervals or treating them as optional also loses points. If your assigned issue is different, such as hypertension control or youth vaping, send the prompt and the data sources required, and an analysis can be written that describes each series before drawing conclusions from it. Charts without labeled survey periods also confuse readers about which years are being compared.
Get an HS830 Unit 4 example written to your instructions
Is the indicator fixed by the prompt, or open? Either answer works; add what your grading criteria expect of charts and sources. Every series gets dated before it is read, its uncertainty is shown, and any causal story is tested for scale. A first custom sample costs nothing and lands within 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More HS830 papers and DHSc samples
- HS830 Unit 1: Vendor Concentration Discussion Post
- HS830 Unit 2: Pediatric Issue Scan With Four Tests
- HS830 Unit 3: Dementia Trend Evidence Appraisal
- HS830 Unit 5: Seminar Reflection
- HS830 Unit 6: Counterargument Memo
- HS830 Unit 7: Horizon Scanning Report
- HS830 Unit 8: Implications Briefing
- HS830 Unit 9: Position Paper
- HS830 Unit 10: Emerging Issue Analysis
- HS820 Unit 4: France Health Financing Analysis
- HS810 Unit 4: Legislative History Brief
HS830 Unit 4 questions, answered
Why not just use the most recent year of data?
Because one point cannot show direction, and the most recent point is often the least stable. Survey cycles get revised, record extracts grow as late data arrives, and a post-pandemic sample may differ in who responded. The sample reads the whole NHANES run from 1999-2000 onward so the latest cycle is judged against its own history.
Are self-reported weights unusable?
No, but they answer a different question. Self-report tends to run low for weight and high for height, so obesity prevalence from phone surveys sits below measured estimates. BRFSS is valuable for state comparisons and annual timing. The sample uses it for those strengths and keeps it off the national trend line, where NHANES carries the claim.
Can a trend analysis make a causal claim?
Carefully, and usually only as a test of plausibility. A trend by itself cannot prove what caused it, but it can rule explanations in or out on scale and timing. The sample asks whether current drug use could plausibly move national prevalence by the amount observed, answers not yet, and names the uptake level at which the question reopens.
Where can I find a free HS830 Unit 4 sample paper?
The full Unit 4 trend data analysis is on this page, comparing NHANES, BRFSS and record-based obesity data and testing the GLP-1 explanation for scale.
Did adult obesity fall in the latest NHANES cycle?
The estimate dropped from 41.9 to 40.3 percent, but NCHS did not report the change as statistically significant, so the paper describes a plateau rather than a decline.